CN113425723A - Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis - Google Patents
Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis Download PDFInfo
- Publication number
- CN113425723A CN113425723A CN202110845027.0A CN202110845027A CN113425723A CN 113425723 A CN113425723 A CN 113425723A CN 202110845027 A CN202110845027 A CN 202110845027A CN 113425723 A CN113425723 A CN 113425723A
- Authority
- CN
- China
- Prior art keywords
- pim1
- ankylosing spondylitis
- preventing
- molecule inhibitor
- small
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010002556 Ankylosing Spondylitis Diseases 0.000 title claims abstract description 62
- 101150056413 Pim1 gene Proteins 0.000 title claims abstract description 46
- 239000003112 inhibitor Substances 0.000 title claims abstract description 35
- 150000003384 small molecules Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 5
- MCUJKPPARUPFJM-UWCCDQBKSA-N (5z)-5-[[2-[(3r)-3-aminopiperidin-1-yl]-3-phenylphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1[C@H](N)CCCN1C(C(=CC=C1)C=2C=CC=CC=2)=C1\C=C/1C(=O)NC(=O)S\1 MCUJKPPARUPFJM-UWCCDQBKSA-N 0.000 claims abstract description 25
- 230000004069 differentiation Effects 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 102000013691 Interleukin-17 Human genes 0.000 abstract description 25
- 108050003558 Interleukin-17 Proteins 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 16
- 238000001727 in vivo Methods 0.000 abstract description 8
- 238000012404 In vitro experiment Methods 0.000 abstract description 6
- 230000028327 secretion Effects 0.000 abstract description 5
- 230000000903 blocking effect Effects 0.000 abstract description 4
- 101100297649 Danio rerio pim2 gene Proteins 0.000 abstract description 3
- 101100297656 Xenopus laevis pim3 gene Proteins 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 2
- 238000011144 upstream manufacturing Methods 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229960004540 secukinumab Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100084595 Caenorhabditis elegans pam-1 gene Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000012282 inflammatory low back pain Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medical biology, and particularly relates to an application of a Pim1 small-molecule inhibitor in preparation of a product for preventing and treating ankylosing spondylitis, wherein a specific small-molecule inhibitor AZD1208 of Pim1 is used, in-vivo and in-vitro experiments prove that Pim1 plays an important role in Th17 differentiation, so that Pim1 can be used AS a target for blocking Th17 differentiation and IL-17A secretion, and the safety, effectiveness and feasibility of using AZD1208 to treat AS are verified. Compared with the IL-17A monoclonal antibody, the pim1 treats the AS by blocking Th17 differentiation, and is positioned upstream of the effect of the IL-17A monoclonal antibody in mechanism, so the invention can provide a new target and a new way for treating the AS and provides a new choice for AS patients, particularly patients with poor treatment effect of the IL-17A monoclonal antibody.
Description
Technical Field
The invention belongs to the technical field of medical biology, and particularly relates to an application of a Pim1 small-molecule inhibitor in preparation of a product for preventing and treating ankylosing spondylitis.
Background
Ankylosing Spondylitis (AS) is a common autoimmune disease. The incidence of AS is high, about 0.2-0.54% in China, and the ratio of male to female is 2-3:1, which is better for young and strong people. The AS is characterized by chronic progressive inflammation and pathological osteogenesis which affect the central axial bone joint, the clinical manifestations are inflammatory low back pain and central axial bone joint ankylosis deformity, in the chronic progress of the disease, the labor capacity of the patient is gradually reduced and even lost, and the life quality is seriously influenced. Because AS can not be completely cured, the method brings heavy economic burden to countries and individuals.
At present, the pathogenesis of AS is not completely elucidated, but more and more researches in recent years show that Th17 cells and IL-17A secreted by the Th17 cells play an important role in promoting the generation and development of AS. Th17 is caused by peripheral blood
T cells develop, the differentiation level of the T cells is in positive correlation with the activity of AS diseases, and the secreted IL-17A participates in a plurality of processes of AS pathophysiology. IL-17A plays a promoting role in the early stage of AS functioning AS the stop inflammation to mediate inflammation, and IL-17A also serves AS an amplifier of the stop inflammation to induce local interstitial cells to generate inflammatory factors to participate in the reaction process of inflammation. In bone tissue, IL-17A inhibits osteoblasts and chondrocytes from producing a matrix, induces osteoblasts to express RANKL, activates osteoclasts, and causes bone destruction. In addition, IL-17A plays a role in sensitizing the symptoms of low back pain of AS patients, and IL-17A enables the patients to be more sensitive to inflammatory stimulation by reducing the stimulation threshold of pain receptors, so that the patients feel stronger pain.
At present, the drugs for clinically treating AS mainly include nonsteroidal anti-inflammatory drugs (NSAIDs), Tumor Necrosis Factor Inhibitors (TNFi), disease-relieving antirheumatic drugs (DMARDs), and the like. The NSAIDs can improve symptoms of low back pain, morning stiffness and joint pain of partial patients, but the treatment response of partial patients to the NSAIDs is poor and the side effect is obvious after long-term administration. DMARDs are mainly used to treat peripheral arthritis, but have poor therapeutic effect on spine disease-predominant AS. TNFa can block the activity of TNF and inhibit the progress of pathological changes, and is suitable for patients with symptoms outside the relevant segment and without the treatment effect of NSAIDs. Based on the important role and clinical evaluation of IL-17A in the generation and development of AS, the IL-17A monoclonal antibody secukinumab is approved for treating AS in 2020 in China. Although Secukinumab shows a certain therapeutic effect clinically, the effect is still poor for some AS patients. In addition, Secukinumab is expensive, and its use causes a large economic burden on most patients, and thus its universality is not high. Therefore, there is a need to explore new AS therapeutic targets and to find small molecule inhibitors that specifically inhibit the target in order to bring safe and effective new methods for the clinical treatment of AS.
Disclosure of Invention
In order to overcome the defects of the prior art, in vivo and in vitro experiments show that the specific small molecule inhibitors of Pim1 such as AZD1208 and the like can effectively prevent and treat the ankylosing spondylitis by taking Pim1 as a new target, and provide a new target and a new way for preventing and treating the ankylosing spondylitis.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention aims to provide application of a Pim1 small-molecule inhibitor in preparation of a product for preventing and treating ankylosing spondylitis, wherein the Pim1 small-molecule inhibitor is a biological functional molecule with the molecular weight of less than 1000 Da.
Preferably, the Pim1 small molecule inhibitor includes, but is not limited to, the Pim1 specific inhibitor AZD 1208.
The molecular formula of AZD1208 is C21H21N3O2S, molecular weight 379.48, structure shown below:
th17 and IL-17A secreted by the same play an important role in the generation and development of AS, and currently, monoclonal antibodies antagonizing IL-17A are clinically used for treating AS, but the treatment effect on partial patients is still poor.
Th17 is derived from
CD4+ T cells, the differentiation of which includes the steps of activation, proliferation and differentiation, are involved in a plurality of Ca2+ related pathways at a molecular level and the phosphorylation of a plurality of proteins, and Th17 and IL-17A secreted by the Th17 play an important role in the generation and development of AS. Pim1 is a phosphorylation kinase in cells, can bind and phosphorylate proteins, can regulate the Ca2+ pathway in cells, has anti-apoptosis and proliferation promoting effects, and therefore, may be a potential target for regulating Th17 differentiation.
Therefore, the invention starts from the source of IL-17A, explores a target point for inhibiting Th17 differentiation, blocks IL-17A secretion, starts with small molecular compounds, and explores safe, effective and highly universal drugs for treating AS. The invention takes Pim1 AS a new AS treatment target, finds that a specific small molecule inhibitor AZD1208 using Pim1 can inhibit the differentiation of CD4+ T cells to Th17, blocks the secretion of IL-17A at the source, has better curative effect on AS, shows better anti-inflammatory effect in vivo and in vitro experiments, and also shows the characteristic of low toxicity. The small-molecule Pim1 inhibitor is used for effectively preventing and treating AS by taking Pim1 AS a target.
Preferably, the prevention and treatment of ankylosing spondylitis is inhibition of differentiation of Th 17.
Preferably, the product for preventing and treating ankylosing spondylitis includes, but is not limited to, medicaments for preventing and treating ankylosing spondylitis and health-care functional foods for preventing and treating ankylosing spondylitis.
The second purpose of the invention is to provide a drug for preventing and treating ankylosing spondylitis, which takes Pim1 small-molecule inhibitor as a main active ingredient.
Preferably, the Pim1 small molecule inhibitor includes, but is not limited to, the Pim1 specific inhibitor AZD 1208.
Preferably, in order to improve the application range of the medicine, the medicine also comprises a pharmaceutically acceptable carrier and/or an auxiliary material. The carrier and/or adjuvant comprises sour agent, toning agent, flavoring agent, sweetening agent, or their combination.
Preferably, the dosage form of the medicament includes, but is not limited to, injection, oral liquid, tablet, granule, capsule, and pill.
The third purpose of the invention is to provide a health-care functional food for preventing and treating ankylosing spondylitis, which takes Pim1 small-molecule inhibitor as a main active ingredient.
Preferably, the Pim1 small molecule inhibitor includes, but is not limited to, the Pim1 specific inhibitor AZD 1208.
Preferably, to increase the applicability of the food product, the food product further comprises a food acceptable carrier and/or auxiliary material. The carrier and/or adjuvant comprises diluent, excipient, filler, binder, humectant, disintegrating agent, absorption enhancer, sweetener, flavoring agent, or their combination.
Preferably, the food product is in the form of, but not limited to, a decoction, a beverage, a candy, an oral liquid, a capsule, a tablet, and a powder.
Compared with the prior art, the invention has the beneficial effects that:
the invention uses a specific small molecule inhibitor AZD1208 of Pim1, proves the important function of Pim1 in Th17 differentiation through in vivo and in vitro experiments, proves that Pim1 can be used AS a target for blocking Th17 differentiation and IL-17A secretion, and verifies the safety, effectiveness and feasibility of using AZD1208 to treat AS. Meanwhile, compared with the IL-17A monoclonal antibody, the pim1 treats the AS by blocking Th17 differentiation, and is positioned upstream of the IL-17A in mechanism, so the invention can provide a new target and a new way for treating the AS and provides a new choice for AS patients, particularly patients with poor treatment effect of the IL-17A monoclonal antibody.
Drawings
FIG. 1 is a flow chart of an experiment of example 1;
FIG. 2 shows Pim1 expression during differentiation of CD4+ T cells to Th 17;
FIG. 3 is a graph of differentiation of CD4+ T cells to Th17 following treatment with AZD1208 inhibitor;
figure 4 is a graph of the toxic effect of AZD1208 on CD4+ T cells;
FIG. 5 shows the arthritis scores of CIA mice treated with the pam 1-specific inhibitor AZD1208 after injection;
FIG. 6 shows changes in liver and kidney function indexes of CIA mice treated with the injection of the specific inhibitor AZD1208 of pim 1.
Detailed Description
The following further describes the embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
The experimental procedures in the following examples were carried out by conventional methods unless otherwise specified, and the test materials used in the following examples were commercially available by conventional methods unless otherwise specified.
Example 1 Pim1 Small molecule inhibitor has curative effect on ankylosing spondylitis by inhibiting Th17 differentiation
The experimental flow is shown in fig. 1, and the specific process is as follows:
1. in vitro experiments
(1) Inhibition of Pim1 effect on Th17 differentiation
CD4+ T cells were sorted from human peripheral blood mononuclear cells (from healthy blood donated volunteers) using human CD4 magnetic beads (purchased from America whirlpool, cat # 130-:
adding peripheral blood gently onto Ficoll separating medium at volume ratio of 1:1, centrifuging at 400g rotation speed (acceleration 1, deceleration 0) for 35min, carefully sucking white membrane layer with Pasteur pipette, washing with PBS twice, centrifuging to remove supernatant, suspending cells with 1640 medium containing 10% FBS, counting, and culturing at each 10%62uL of magnetic beads and 8uLbuffer (PBS 100mL + 0.5% BSA (0.5g) +2mM EDTA (0.654 g)) were added to each cell, the pH was adjusted to 7.2 with NaOH, and the mixture was sterilized by filtration, mixed well, and incubated at 4 ℃ for 15 minutes in the dark.Adding an appropriate amount of buffer, centrifuging for 10min at 300g, discarding the supernatant, and mixing with 500. mu.L of buffer/108And resuspending the cells. Placing the separation column on a magnetic frame, moistening with a buffer, injecting cells into the separation column, washing with the buffer for 3 times, taking the separation column off the magnetic frame, adding 1mL of buffer, washing out the cells in the separation column, centrifuging for 5min at 1500 rpm, discarding the supernatant, resuspending with 1mL of 1640 medium containing 10% FBS, counting, and performing 0.6 × 106Cell/well plate.
Under the polarization condition of Th17 (anti-CD 31 ug/mL, anti-CD 281 ug/mL, IL-2330 ng/mL, IL-620 ng/mL and TGF-beta 5ng/mL), CD4+ T cells are induced to differentiate to Th17, and meanwhile, a pim1 specific small molecule inhibitor AZD 120820 uM or an equal volume of DMSO is given to treat the cells, and after 3 days of culture, the proportion of Th17 differentiation is detected by flow cytometry by taking CD4 and IL-17A as markers.
As shown in fig. 2 and fig. 3, it was found that expression of Pim1 was up-regulated during differentiation of CD4+ T cells to Th17, but the proportion of Th17 differentiation was significantly decreased after inhibiting Pim1 activity using AZD 1208;
(2) toxicity of AZD1208 inhibitors on CD4+ T cells
The toxicity of the drug on the cells was detected using CCK-8 enzyme-labeled assay. The specific detection is as follows: to a 96-well plate, 100uL of Th17 polarization-cultured CD4+ T cells (about 5000 cells) were added, and AZD1208 or an equal volume of DMSO was added, respectively, while a cell-free culture solution was added as a blank, and 5 duplicate wells were set for each group. To each well, 10uL of CCK-8 solution was added, incubated for 2 hours, and absorbance was measured at 450nm using a microplate reader. In the detection range, the absorbance at 450nm is approximately proportional to the cell activity.
As shown in figure 4, inhibition of Pim1 using AZD1208 was found to be less toxic to CD4+ T cells.
2. In vivo experiments
(1) Inhibition of the therapeutic effect of Pim1 on CIA
As an arthritis-inducing subject, 6-8-week-old DBA/1 female mice (purchased from Jiangsu Geigo Kangbiotech Co., Ltd.) were used, CFA (Freund's complete adjuvant, 1mg/mL) and type II collagen (2mL/mL) were completely emulsified on ice, transferred into a 1mL syringe, centrifuged, and then 100uL was intradermally injected into the groin of each mouse. After 21 days, the mice were boosted (Freund's incomplete adjuvant IFA + type II collagen) to establish a collagen-induced arthritis model (CIA), and 5 CIA mice per group were divided into an experimental group and a control group. AZD1208 was dissolved in DMSO to make a 60mg/mL solution and diluted with methylcellulose to a 3mg/mL suspension, and the CIA was treated by gavage with AZD1208 (control: equivalent ratio of methylcellulose to DMSO) at a dose of 1 dose per day at 30mg/kg body weight for 21 consecutive doses, with an arthritis score every 3 days.
As shown in fig. 5, after 21 days of continuous administration, AZD1208, a specific small molecule inhibitor of Pim1, was found to significantly reduce the arthritis score in CIA mice.
(2) Toxic effects of AZD1208 inhibitors in vivo
After the above CIA mice were continuously administered for 21 days, the mice were sacrificed by dislocation of the spine on day 21, and peripheral blood indices for detecting liver and kidney functions [ detection of serum aspartate Aminotransferase (AST) by MDH method, detection of alanine Aminotransferase (ALT) by lactate dehydrogenase method, detection of serum creatinine (Scr) by picric acid method, and detection of serum urea nitrogen (BUN) by urease-glutamate dehydrogenase method ] were collected. As shown in figure 6, it was found that inhibition of Pim1 activity in vivo using AZD1208 did not cause severe impairment of hepatic and renal function.
The experiments show that the Pim1 specific small molecule inhibitor AZD1208 can inhibit CD4+ T cells from differentiating to Th17, block the secretion of IL-17A at the source, has a good curative effect on Ankylosing Spondylitis (AS), shows a good anti-inflammatory effect in both in vivo and in vitro experiments, and also shows the characteristic of low toxicity. It can be seen that Pim1 can be a new target for AS therapy.
The embodiments of the present invention have been described in detail, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.
Claims (10)
- The application of the Pim1 small-molecule inhibitor in preparing a product for preventing and treating ankylosing spondylitis is characterized in that the Pim1 small-molecule inhibitor is a biological functional molecule with the molecular weight of less than 1000 Da.
- 2. The use as claimed in claim 1 wherein the small molecule inhibitor of Pim1 includes but is not limited to the specific inhibitor AZD1208 of Pim 1.
- 3. The use according to claim 1, wherein the prevention and treatment of ankylosing spondylitis is the inhibition of Th17 differentiation.
- 4. The use according to claim 1, wherein the ankylosing spondylitis prevention and treatment product comprises but is not limited to a drug for ankylosing spondylitis and a health-care functional food for ankylosing spondylitis.
- 5. A medicine for preventing and treating ankylosing spondylitis is characterized in that a Pim1 small-molecule inhibitor is used as a main active ingredient.
- 6. The medicament for preventing and treating ankylosing spondylitis according to claim 5, further comprising a pharmaceutically acceptable carrier and/or adjuvant.
- 7. The medicament for preventing and treating ankylosing spondylitis according to claim 5, wherein the dosage form of the medicament includes, but is not limited to, injection, oral liquid, tablet, granule, capsule, pill.
- 8. A health-care functional food for preventing and treating ankylosing spondylitis is characterized in that a Pim1 small-molecule inhibitor is used as a main active ingredient.
- 9. The health-care functional food for preventing and treating ankylosing spondylitis of claim 8, further comprising a food-acceptable carrier and/or an auxiliary material.
- 10. The health-care functional food for preventing and treating ankylosing spondylitis as claimed in claim 8, wherein the form of the food includes, but is not limited to, decoctions, beverages, candies, oral liquids, capsules, tablets and powders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110845027.0A CN113425723B (en) | 2021-07-26 | 2021-07-26 | Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110845027.0A CN113425723B (en) | 2021-07-26 | 2021-07-26 | Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113425723A true CN113425723A (en) | 2021-09-24 |
| CN113425723B CN113425723B (en) | 2022-12-06 |
Family
ID=77761778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110845027.0A Active CN113425723B (en) | 2021-07-26 | 2021-07-26 | Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113425723B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107661501A (en) * | 2017-11-03 | 2018-02-06 | 中山大学孙逸仙纪念医院 | A kind of pharmaceutical composition for treating ankylosing spondylitis, drug target and its application |
| CN112336863A (en) * | 2020-11-26 | 2021-02-09 | 中山大学附属第八医院（深圳福田） | Application of S1P receptor inhibitor in preparation of product for preventing and treating ankylosing spondylitis |
-
2021
- 2021-07-26 CN CN202110845027.0A patent/CN113425723B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107661501A (en) * | 2017-11-03 | 2018-02-06 | 中山大学孙逸仙纪念医院 | A kind of pharmaceutical composition for treating ankylosing spondylitis, drug target and its application |
| CN112336863A (en) * | 2020-11-26 | 2021-02-09 | 中山大学附属第八医院（深圳福田） | Application of S1P receptor inhibitor in preparation of product for preventing and treating ankylosing spondylitis |
Non-Patent Citations (4)
| Title |
|---|
| BRETT A. LINOWES,ET AL: ""Pim1 permits generation and survival of CD4+ T cells in the absence of γc cytokine receptor signaling"", 《EUR J IMMUNOL.》 * |
| DAI HORIUCHI ET AL: ""PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression"", 《NAT MED》 * |
| ERIKA K KEETON，ET AL: ""AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia"", 《BLOOD》 * |
| SAYAM DUBASH,ET AL: ""The advent of IL-17A blockade in ankylosing"", 《EXPERT REVIEW OF CLINICAL IMMUNOLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113425723B (en) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019149156A1 (en) | Uses of pulsatilla chinensis extract in preparing drug for treating viral and/or bacterial diseases | |
| CA2901421A1 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| EP2543385A1 (en) | Novel analgesics | |
| JP3721196B2 (en) | Use of magnesium-based products for the treatment or prevention of neoplastic and autoimmune diseases | |
| WO2023092943A1 (en) | Use of dronedarone hydrochloride in combination with 5-fluorouracil in preparation of anti-tumor drug | |
| CN109939119B (en) | Application of geniposide in preparation of medicine for treating multiple sclerosis | |
| US20130164382A1 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| CN116019813B (en) | Use of Vesatolimod in the preparation of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system | |
| CN113425723B (en) | Application of Pim1 small-molecule inhibitor in preparation of product for preventing and treating ankylosing spondylitis | |
| JPH06199695A (en) | Agent for amelioration and treatment of diabetes | |
| CN113747904A (en) | Application of vaccinia virus inflammation-causing rabbit fur extract in treating hematopoietic system injury | |
| CN116098918A (en) | Citicoline pharmaceutical composition and application thereof | |
| CN112807292B (en) | Application of bunge auriculate root benzophenone in preparation of uric acid reducing medicines | |
| AU2010305251B2 (en) | Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin B12 and Vitamin B6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing | |
| CN117357511A (en) | Application of Ginkgetin in preparation of STING inhibitor | |
| CN114832006A (en) | Application of ginsenoside Rh4 in preparation of medicine for inhibiting sleep | |
| CN114699410A (en) | Application of cepharanthine in preparing medicine for treating rheumatoid arthritis | |
| CN113384591A (en) | Combined drug of trametes acid and sorafenib and application of combined drug in preparation of antitumor drug | |
| EP0476391B1 (en) | Anti-AIDS virus composition containing cepharanthine as active compound | |
| CN112618569A (en) | Medicine for treating urothelial cancer | |
| CN108785300B (en) | Application of alpha-mangostin in preparation of medicine for preventing and treating gout and hyperuricemia | |
| TW202133866A (en) | Mycelium of liquid culture of antrodia camphorata extract, compounds of mycelium of liquid culture of antrodia camphorata extract, and use thereof for treating ischemic stroke | |
| CN105434432B (en) | N-Hydroxyphthalimide class compound application in preparation of anti-tumor drugs | |
| CN117298086B (en) | Application of sofalcone in preparation of medicines for preventing and/or treating NLRP3 inflammatory corpuscle mediated diseases | |
| KR101086040B1 (en) | Asiatic acid derivatives for the therapeutical treatment of hepatic fibrosis and liver cirrhosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |